Peptides are a diverse group of molecules, and some have genuinely interesting uses. These 10 peptides to know are an educational selection, not a popularity list or a ranking of the best products. Two have FDA-approved uses in specific populations; for others, promising mechanisms or early studies still leave the everyday wellness benefit unproven. Start with the benefit you care about, then check whether people—not just cells or animals—were studied for that outcome.
A quick way to read the evidence
An approved indication means a specific medicine has evidence for a defined condition and population, not that it works for everyone or for every goal. A small human trial can be encouraging without settling the question; a hormone or laboratory change is not automatically a change in health or daily life. Animal and cell findings are starting points, not demonstrated benefits for people. The numbers below organize an educational overview—not a top-10 ranking by effectiveness, popularity, or search traffic.[2][3][8][9]
1. Tesamorelin — abdominal fat in a defined medical setting
Why the interest: its effect on fat stored inside the abdomen. Evidence tier: FDA-approved, indication-specific human trials. In adults with HIV and lipodystrophy (an abnormal fat-distribution condition), placebo-controlled studies measured a reduction in visceral abdominal fat. The EGRIFTA SV label expressly says it is not indicated for weight-loss management; these findings are not evidence of general fat loss or a wellness benefit in otherwise healthy adults.[2]
2. Bremelanotide — sexual desire in a specific population
Why the interest: sexual desire. Evidence tier: FDA-approved, indication-specific human trials. VYLEESI's label reports two placebo-controlled studies in premenopausal women with acquired, generalized hypoactive sexual desire disorder, a defined condition involving distress about low desire. Desire and related distress improved on the study measures, but the number of satisfying sexual events did not differ significantly. This is not a general libido or relationship-enhancement claim.[13]
3. Sermorelin — stimulating growth hormone release
Why the interest: prompting the body's own growth-hormone signal. Evidence tier: limited human clinical evidence. Sermorelin is growth hormone-releasing hormone (1–29)-NH2; a randomized six-month study in 60 children with growth-hormone deficiency of hypothalamic origin measured growth while comparing this molecule with growth hormone. Children in the growth-hormone group grew significantly faster. A study in children with a diagnosed deficiency does not establish muscle, recovery, or anti-aging benefits for healthy adults.[6]
4. Ipamorelin — hormone response and gut-motility research
Why the interest: growth-hormone release and possible support for bowel movement after surgery. Evidence tier: human pharmacology plus a clinical trial without a demonstrated benefit. A volunteer study measured a short-lived growth-hormone response, not improved body composition. In a placebo-controlled study of adults recovering from bowel resection, key and secondary measures of postoperative bowel recovery did not significantly differ. Neither result establishes recovery or physique benefits in healthy people.[7][14]
5. CJC-1295 — sustained hormone signals
Why the interest: longer-lasting changes in growth hormone and IGF-1, a related growth signal. Evidence tier: short human pharmacology studies, not clinical-benefit trials. Placebo-controlled research in healthy adults reported sustained hormone changes, but did not show better strength, body composition, recovery, or longevity. FDA's review notes that CJC-1295 names can refer to different forms; results from the studied form must not be applied to every similarly named product.[8][15]
Visit the store directly, or keep exploring the evidence library. No email signup is needed to visit the store.
6. BPC-157 — repair and healing hypotheses
Why the interest: proposed tissue repair. Evidence tier: mostly animal studies; human benefit not established. Rat wound experiments generated the healing hypothesis. FDA's May 2026 review identified a small, varied human literature, including exploratory or uncontrolled reports, and found insufficient evidence for effectiveness in the uses it assessed. Those reports do not demonstrate faster healing or relief of everyday injuries in people.[3][16]
7. TB-500 — a proposed repair fragment
Why the interest: possible wound repair. Evidence tier: preclinical/identity research, without identified human TB-500 outcome studies. FDA's May 2026 evaluation describes the assessed TB-500 as an acetylated seven-amino-acid fragment, Ac-LKKTETQ, and found no human clinical or exposure data for it in its search. Mouse research on a related fragment is a reason to investigate, not proof of a human healing benefit. TB-500 is not the same molecule as full-length thymosin beta-4 below.[9][17]
8. GHK-Cu — skin appearance research
Why the interest: skin recovery and appearance. Evidence tier: very small topical human trial, with mixed outcomes. In 13 people completing a randomized study after facial laser resurfacing, topical GHK-Cu products did not significantly improve objectively assessed redness, wrinkles, or skin quality compared with control; questionnaire-reported skin-quality satisfaction was higher. This topical result does not establish a general anti-aging effect or a benefit for other forms of GHK-Cu.[10]
9. Thymosin alpha-1 — immune-response research
Why the interest: immune responses in specific illnesses. Evidence tier: human disease-specific study, not proof of general immune boosting. A randomized study of 316 Japanese patients with chronic hepatitis B compared two thymosin alpha-1 treatment groups and reported viral and liver-enzyme outcomes. Because it did not include an untreated or placebo group, its results cannot establish the size of a benefit over no treatment. It says nothing about preventing infections or improving immunity in healthy adults.[11]
10. Thymosin beta-4 — early dry-eye research
Why the interest: tissue repair, including the eye's surface. Evidence tier: small human placebo-controlled trial in a specific condition. A phase 2 study of full-length thymosin beta-4 eye drops in nine people with severe dry eye reported improvements in eye-discomfort and corneal-staining measures. That is an early, narrow result—not proof of general injury recovery—and cannot be transferred to the shorter TB-500 fragment.[12][9]
How to use this overview
Bring the exact product name and the outcome you hope for to a licensed clinician. Ask whether a human study tested that same molecule, form, and goal in people like you, and what is known about adverse effects and interactions. FDA-approved medicines have specific labels; supplements are not pre-approved for safety and effectiveness, and compounded drugs are not FDA-approved. A research-use label is not an efficacy finding. These distinctions help keep an interesting idea separate from an established personal benefit.[1][2][4][5]
At a glance
| Topic | Evidence level | What that means for a benefit claim |
|---|---|---|
| Specific approved use[2][13] | Tesamorelin and bremelanotide have defined labeled uses. | Human trial results apply to their studied conditions and populations, not to broad wellness claims. |
| Human signals, limited translation[6][7][8][10][11][12][14] | Sermorelin, ipamorelin, CJC-1295, GHK-Cu, thymosin alpha-1, and thymosin beta-4 have differing human study records. | Check the actual endpoint, comparator, form, and population before describing a benefit. |
| Mostly preclinical or exploratory[3][9][16][17] | BPC-157 and TB-500 attract interest for proposed repair. | Animal studies and limited or absent human outcome studies do not establish healing benefits for people. |
Questions readers ask
Are these the 10 best or most popular peptides?
No. They are 10 individual molecules selected to illustrate different interests and evidence levels, not a ranking by benefit, demand, popularity, or search volume.[2][3][9][13]
Does a rise in growth hormone mean better recovery?
Not by itself. Ipamorelin and CJC-1295 studies measured hormone responses, which are not the same as demonstrated improvements in strength, healing, or function.[7][8]
Sources
References
- Information for Consumers on Using Dietary SupplementsFDA consumer guidance; supplement premarket approval distinction and consultation advice.
- EGRIFTA SV (tesamorelin) prescribing informationDailyMed label, effective July 29, 2026; indication, trial population, visceral-fat endpoint and weight-loss limitation.
- FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate)Dated May 11, 2026; human versus nonclinical evidence inventory and limitations, not a final approval decision.
- Compounding and the FDA: Questions and AnswersFDA explanation that compounded drugs are not FDA-approved.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA substance-specific interim-policy safety page; not a blanket finding about all peptides.
- A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiencyChen et al., 1993; randomized 60-child comparison; growth endpoint in diagnosed hypothalamic deficiency.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersGobburu et al., 1999; healthy-volunteer growth-hormone response, not clinical benefit.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsTeichman et al., 2006; placebo-controlled healthy-adult hormone endpoints.
- FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate)Dated May 15, 2026; fragment identity and human-evidence search, not a final approval decision.
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skinMiller et al., 2006; 13 completers in a randomized topical study; objective and patient-reported outcomes differ.
- The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trialIino et al., 2005; randomized between active regimens, not versus placebo or untreated control.
- Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trialSosne et al., 2015; nine patients, full-length thymosin beta-4 eye drops versus vehicle.
- VYLEESI (bremelanotide) prescribing informationDailyMed label; defined indication, two phase 3 trials, desire/distress endpoints and nonsignificant satisfying-sexual-events endpoint.
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsBeck et al., 2014; postoperative human trial with no significant key or secondary efficacy differences.
- FDA Evaluation of CJC-1295-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances ListDated November 15, 2024; form/naming ambiguity and limited human evidence.
- BPC 157's effect on healingSeiwerth et al., 1997; wound-healing experiments in rats, not human clinical outcomes.
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged micePhilp et al., 2003; mouse research on full-length peptide and related fragment, not human TB-500 benefit.